Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00733
|
|||||
| Drug Name |
Dihydrotestosterone
|
|||||
| Synonyms |
17beta-Hydroxy-3-androstanone; 17beta-Hydroxy-5alpha-androstan-3-one; 17beta-Hydroxyandrostan-3-one; 4,5alpha-Dihydrotestosterone; 4-Dihydrotestosterone; 5-alpha-Dihydrotestosterone; 521-18-6; 5alpha-Androstan-17beta-ol-3-one; 5alpha-DHT; 5alpha-Dihydrotestosterone; Anaboleen; Anabolex; Andractim; Androlone; Androstanolona; Androstanolone; Androstanolonum; Cristerona MB; DHT; Dihydrotestosteron; LG 152; Neodrol; Proteina; Protona; STANOLONE; Stanaprol; Stanolon; Stanorone; Testosterone, dihydro-; [3H]dihydrotestosterone; dihydrotestosterone
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Female hypogonadism [ICD11: 5A61.0] | Phase 2 | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C19H30O2
|
|||||
| Canonical SMILES |
CC12CCC(=O)CC1CCC3C2CCC4(C3CCC4O)C
|
|||||
| InChI |
InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12,14-17,21H,3-11H2,1-2H3/t12-,14-,15-,16-,17-,18-,19-/m0/s1
|
|||||
| InChIKey |
NVKAWKQGWWIWPM-ABEVXSGRSA-N
|
|||||
| CAS Number |
CAS 521-18-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 290.4 | Topological Polar Surface Area | 37.3 | ||
| Heavy Atom Count | 21 | Rotatable Bond Count | 0 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 2 | |||
| XLogP |
3.7
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:16330
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | ClinicalTrials.gov (NCT00163566) Study of DHT-Gel to Treat the Symptoms of Low Testosterone in Men 55-80 | |||||
| 2 | P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells. Prostate. 2004 Apr 1;59(1):77-90. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.